Association between anti-C1q antibodies and glomerular tuft necrosis in lupus nephritis

Clinical Nephrology

Volumn 77, Issue 3, 2012, Pages 211-218

  Jourde Chiche, Noémie ^a   Daniel, Laurent ^a   Chiche, Laurent ^a   Burtey, Stéphane ^a   Mancini, Julien ^a   Jego, Sophie ^a   Marco, Marielle San ^a   Bardin, Nathalie ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Anti C1q Antibodies; Glomerular Necrosis; Lupus Nephritis; Renal Vasculitis

Indexed keywords

COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; AUTOANTIBODY; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C1Q;

ADULT; ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; GLOMERULAR TUFT NECROSIS; GLOMERULONEPHRITIS; GLOMERULUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY NECROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; RETROSPECTIVE STUDY; BIOPSY; BLOOD; CHI SQUARE DISTRIBUTION; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NECROSIS; PATHOLOGY; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; BIOPSY; CHI-SQUARE DISTRIBUTION; COMPLEMENT C1Q; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; NECROSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859481166     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107274     Document Type: Article

References (25)

1. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004; 15: 241-250
2. Trendelenburg M, Lopez-Trascasa M, Potlukova E, Moll S, Regenass S, Frémeaux-Bacchi V, Martinez-Ara J, Jancova E, Picazo ML, Honsova E, Tesar V, Sadallah S, Schifferli J. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant. 2006; 21: 3115-3121
3. Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis. 2005; 64: 444-448.
4. Horváth L, Czirják L, Fekete B, Jakab L, Pozsonyi T, Kalabay L, Romics L, Miklós K, Varga L, Prohászka Z, Szakács A, Nagy E, Daha MR, Füst G. High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol. 2001; 19: 667-672
5. Meyer OC, Nicaise-Roland P, Cadoudal N, Grootenboer-Mignot S, Palazzo E, Hayem G, Dieudé P, Chollet-Martin S. Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res Ther. 2009; 11: R87
6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. [Letter]. Arthritis Rheum. 1997; 40: 1725
7. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29: 288-291
8. Fang QY, Yu F, Tan Y, Xu LX, Wu LH, Liu G, Shao FM, Zhao MH. Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis. Nephrol Dial Transplant. 2009; 24: 172-178.
9. Behara VY, Whittier WL, Korbet SM, Schwartz MM, Martens M, Lewis EJ. Pathogenetic features of severe segmental lupus nephritis. Nephrol Dial Transplant. 2010; 25: 153-159
10. Hill GS, Delahousse M, Nochy D, Bariéty J. Class IV-S vs. class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int. 2005; 68: 2288-2297.
11. Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J; Lupus Nephritis Collaborative Study Group. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001; 59: 2156-2163
12. Schwartz MM, Korbet SM, Lewis EJ; Collaborative Study Group. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant. 2008; 23: 1298-1306
13. Schwartz MM, Korbet SM, Katz RS, Lewis EJ. Evidence of concurrent immunopathological mechanisms determining the pathology of severe lupus nephritis. Lupus. 2009; 18: 149-158
14. Sen D, Isenberg DA. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus. 2003; 12: 651-658
15. Galeazzi M, Morozzi G, Sebastiani GD, Bellisai F, Marcolongo R, Cervera R, De Ramòn Garrido E, Fernandez-Nebro A, Houssiau F, Jedryka-Goral A, Mathieu A, Papasteriades C, Piette JC, Scorza R, Smolen J. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol. 1998; 16: 541-546
16. Flierman R, Daha MR. Pathogenic role of anti-C1q autoantibodies in the development of lupus nephritis - a hypothesis. Mol Immunol. 2007; 44: 133-138
17. Taylor PR, Carugati A, Fadok VA, Cook HT, Andrews M, Carroll MC, Savill JS, Henson PM, Botto M, Walport MJ. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med. 2000; 192: 359-366
18. Tsirogianni A, Pipi E, Soufleros K. Relevance of anti-C1q autoantibodies to lupus nephritis. Ann N Y Acad Sci. 2009; 1173: 243-251
19. Bigler C, Schaller M, Perahud I, Osthoff M, Trendelenburg M. Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells. J Immunol. 2009; 183: 3512-3521.
20. Schaller M, Bigler C, Danner D, Ditzel HJ, Trendelenburg M. Autoantibodies against C1q in systemic lupus erythematosus are antigen-driven. J Immunol. 2009; 183: 8225-8231.
21. Wisnieski JJ, Baer AN, Christensen J, Cupps TR, Flagg DN, Jones JV, Katzenstein PL, McFadden ER, McMillen JJ, Pick MA et al. Hypocomplementemic urticarial vasculitis syndrome. Clinical and serologic findings in 18 patients. Medicine (Baltimore). 1995; 74: 24-41
22. Trendelenburg M, Courvoisier S, Späth PJ, Moll S, Mihatsch M, Itin P, Schifferli JA. Hypocomplementemic urticarial vasculitis or systemic lupus erythematosus? Am J Kidney Dis. 1999; 34: 745-751.
23. Furie R, Looney RJ, Rovin B, et al. Efficacy and safety of Rituximab in subjects with active proliferative lupus nephritis: results from the randomized, double-bind phas III LUNAR study. Presented at the ACR meeting, Philadephia, 200924
24. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group. Rituximab vs. cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363: 221-332
25. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM; The Lupus Nephritis Collaborative Study Group. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med. 1992; 326: 1373-1379